Concepts (182)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Atherosclerosis | 9 | 2025 | 160 | 2.410 |
Why?
|
| Cardiovascular Diseases | 5 | 2023 | 866 | 1.650 |
Why?
|
| Oxidative Stress | 7 | 2020 | 323 | 1.570 |
Why?
|
| Aryldialkylphosphatase | 4 | 2015 | 19 | 1.320 |
Why?
|
| Lipoproteins, LDL | 3 | 2025 | 49 | 1.270 |
Why?
|
| Osteoporosis | 1 | 2025 | 112 | 0.860 |
Why?
|
| Bone and Bones | 1 | 2025 | 152 | 0.840 |
Why?
|
| Anemia, Sickle Cell | 1 | 2024 | 66 | 0.820 |
Why?
|
| Machine Learning | 1 | 2025 | 195 | 0.790 |
Why?
|
| Fatty Acids, Omega-3 | 1 | 2023 | 40 | 0.790 |
Why?
|
| Proprotein Convertase 9 | 2 | 2022 | 15 | 0.730 |
Why?
|
| Interleukin-6 | 2 | 2014 | 325 | 0.720 |
Why?
|
| Plaque, Atherosclerotic | 1 | 2022 | 34 | 0.710 |
Why?
|
| Inflammation | 5 | 2022 | 1186 | 0.680 |
Why?
|
| Magnesium | 3 | 2026 | 56 | 0.670 |
Why?
|
| Gastrointestinal Microbiome | 2 | 2026 | 260 | 0.630 |
Why?
|
| Calcinosis | 1 | 2020 | 86 | 0.610 |
Why?
|
| Polyphenols | 1 | 2020 | 61 | 0.600 |
Why?
|
| Triglycerides | 2 | 2012 | 250 | 0.580 |
Why?
|
| Environmental Pollutants | 1 | 2020 | 97 | 0.570 |
Why?
|
| Aortic Valve | 1 | 2020 | 192 | 0.560 |
Why?
|
| Berberine | 1 | 2018 | 4 | 0.550 |
Why?
|
| Hep G2 Cells | 1 | 2018 | 30 | 0.550 |
Why?
|
| Polyesters | 1 | 2018 | 49 | 0.530 |
Why?
|
| Microbiota | 1 | 2020 | 165 | 0.520 |
Why?
|
| Polycystic Ovary Syndrome | 2 | 2014 | 23 | 0.520 |
Why?
|
| Endometriosis | 2 | 2014 | 28 | 0.520 |
Why?
|
| Aortic Valve Stenosis | 1 | 2020 | 195 | 0.520 |
Why?
|
| Lipoprotein(a) | 1 | 2017 | 8 | 0.520 |
Why?
|
| Infertility, Female | 2 | 2014 | 48 | 0.510 |
Why?
|
| Polyethylene Glycols | 1 | 2018 | 174 | 0.490 |
Why?
|
| Ovulation Induction | 2 | 2014 | 14 | 0.480 |
Why?
|
| Blood Platelets | 2 | 2022 | 109 | 0.460 |
Why?
|
| Enzyme Assays | 1 | 2015 | 15 | 0.450 |
Why?
|
| Chemokine CCL2 | 1 | 2014 | 60 | 0.430 |
Why?
|
| Pregnancy Outcome | 2 | 2014 | 203 | 0.420 |
Why?
|
| Humans | 27 | 2026 | 65534 | 0.420 |
Why?
|
| Macrophages | 1 | 2020 | 1060 | 0.410 |
Why?
|
| Lipid Peroxidation | 4 | 2012 | 67 | 0.410 |
Why?
|
| Estradiol | 2 | 2012 | 262 | 0.400 |
Why?
|
| Apolipoproteins A | 1 | 2012 | 1 | 0.380 |
Why?
|
| Stroke | 2 | 2024 | 1215 | 0.380 |
Why?
|
| Biomarkers | 3 | 2014 | 1473 | 0.370 |
Why?
|
| Cognition | 3 | 2025 | 502 | 0.360 |
Why?
|
| Tumor Necrosis Factor-alpha | 1 | 2014 | 623 | 0.350 |
Why?
|
| Nanoparticles | 1 | 2018 | 545 | 0.350 |
Why?
|
| Risk Factors | 6 | 2024 | 5441 | 0.340 |
Why?
|
| Animals | 11 | 2025 | 21533 | 0.320 |
Why?
|
| Polymorphism, Single Nucleotide | 1 | 2012 | 511 | 0.310 |
Why?
|
| Premenopause | 1 | 2010 | 61 | 0.310 |
Why?
|
| Physical Fitness | 1 | 2010 | 92 | 0.310 |
Why?
|
| Dietary Supplements | 2 | 2023 | 239 | 0.300 |
Why?
|
| Linoleic Acid | 2 | 2009 | 20 | 0.300 |
Why?
|
| Myocardial Ischemia | 1 | 2010 | 117 | 0.300 |
Why?
|
| Diet | 4 | 2026 | 539 | 0.290 |
Why?
|
| Colorimetry | 1 | 2008 | 26 | 0.280 |
Why?
|
| Apolipoproteins | 1 | 2008 | 14 | 0.280 |
Why?
|
| Prospective Studies | 5 | 2026 | 3355 | 0.280 |
Why?
|
| Apolipoprotein C-III | 1 | 2008 | 7 | 0.280 |
Why?
|
| Diabetes Mellitus | 3 | 2026 | 555 | 0.270 |
Why?
|
| Reactive Oxygen Species | 1 | 2008 | 242 | 0.260 |
Why?
|
| Motor Activity | 1 | 2010 | 346 | 0.260 |
Why?
|
| Female | 12 | 2026 | 34113 | 0.250 |
Why?
|
| Adult | 8 | 2026 | 17409 | 0.240 |
Why?
|
| Osteoprotegerin | 1 | 2025 | 6 | 0.230 |
Why?
|
| Receptor Activator of Nuclear Factor-kappa B | 1 | 2025 | 7 | 0.230 |
Why?
|
| Sleep Initiation and Maintenance Disorders | 1 | 2026 | 47 | 0.230 |
Why?
|
| Proton Pump Inhibitors | 1 | 2026 | 47 | 0.230 |
Why?
|
| RANK Ligand | 1 | 2025 | 23 | 0.230 |
Why?
|
| Puerto Rico | 4 | 2026 | 141 | 0.220 |
Why?
|
| Hypertension | 2 | 2022 | 613 | 0.210 |
Why?
|
| Antioxidants | 4 | 2010 | 266 | 0.210 |
Why?
|
| Eicosapentaenoic Acid | 1 | 2023 | 18 | 0.200 |
Why?
|
| Docosahexaenoic Acids | 1 | 2023 | 32 | 0.200 |
Why?
|
| Male | 10 | 2026 | 31065 | 0.200 |
Why?
|
| Middle Aged | 8 | 2026 | 18261 | 0.200 |
Why?
|
| Signal Transduction | 2 | 2025 | 3152 | 0.190 |
Why?
|
| Hypoglycemic Agents | 1 | 2024 | 224 | 0.180 |
Why?
|
| Serotonin | 1 | 2022 | 62 | 0.180 |
Why?
|
| Gene Expression Regulation | 2 | 2020 | 1638 | 0.170 |
Why?
|
| Glutathione Peroxidase | 2 | 2012 | 29 | 0.170 |
Why?
|
| Boston | 3 | 2026 | 260 | 0.170 |
Why?
|
| White Matter | 1 | 2022 | 125 | 0.170 |
Why?
|
| Apolipoprotein A-V | 2 | 2012 | 2 | 0.170 |
Why?
|
| Insulin Resistance | 1 | 2024 | 413 | 0.170 |
Why?
|
| Biophysics | 1 | 2020 | 42 | 0.160 |
Why?
|
| Acute Coronary Syndrome | 1 | 2023 | 254 | 0.160 |
Why?
|
| RAW 264.7 Cells | 1 | 2020 | 56 | 0.160 |
Why?
|
| Aging | 1 | 2025 | 766 | 0.150 |
Why?
|
| Superoxide Dismutase | 2 | 2012 | 226 | 0.150 |
Why?
|
| Fatty Acids | 2 | 2012 | 205 | 0.150 |
Why?
|
| Depression | 1 | 2026 | 916 | 0.150 |
Why?
|
| Aldehydes | 2 | 2009 | 13 | 0.150 |
Why?
|
| Diabetes Mellitus, Type 2 | 2 | 2024 | 726 | 0.140 |
Why?
|
| C-Reactive Protein | 2 | 2010 | 167 | 0.140 |
Why?
|
| Cell Membrane | 1 | 2020 | 510 | 0.130 |
Why?
|
| Lipoproteins | 2 | 2010 | 85 | 0.130 |
Why?
|
| Risk Assessment | 1 | 2024 | 2101 | 0.130 |
Why?
|
| Brain | 1 | 2025 | 1606 | 0.130 |
Why?
|
| Platelet Aggregation | 2 | 2022 | 26 | 0.120 |
Why?
|
| Pregnancy | 2 | 2014 | 2432 | 0.120 |
Why?
|
| Cholesterol | 2 | 2008 | 263 | 0.110 |
Why?
|
| Hemolysis | 1 | 2015 | 41 | 0.110 |
Why?
|
| Gonadotropins | 1 | 2014 | 14 | 0.110 |
Why?
|
| Statistics, Nonparametric | 1 | 2015 | 214 | 0.110 |
Why?
|
| Drug Delivery Systems | 1 | 2018 | 334 | 0.110 |
Why?
|
| Aspirin | 2 | 2022 | 172 | 0.100 |
Why?
|
| Mice | 5 | 2020 | 11209 | 0.100 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 1 | 2015 | 460 | 0.100 |
Why?
|
| Sex Factors | 2 | 2023 | 997 | 0.100 |
Why?
|
| Oxidation-Reduction | 3 | 2010 | 331 | 0.100 |
Why?
|
| Dinoprost | 1 | 2012 | 19 | 0.090 |
Why?
|
| Sperm Injections, Intracytoplasmic | 1 | 2012 | 32 | 0.090 |
Why?
|
| Pregnancy Rate | 1 | 2012 | 31 | 0.090 |
Why?
|
| Aged | 5 | 2026 | 14941 | 0.090 |
Why?
|
| Fertilization in Vitro | 1 | 2012 | 85 | 0.090 |
Why?
|
| Carboxylic Acids | 2 | 2009 | 9 | 0.090 |
Why?
|
| Metabolic Syndrome | 1 | 2012 | 147 | 0.080 |
Why?
|
| Anticoagulants | 1 | 2015 | 519 | 0.080 |
Why?
|
| PPAR alpha | 2 | 2008 | 34 | 0.080 |
Why?
|
| Lipids | 2 | 2010 | 328 | 0.080 |
Why?
|
| Longitudinal Studies | 2 | 2026 | 1287 | 0.080 |
Why?
|
| Reproducibility of Results | 1 | 2015 | 1700 | 0.080 |
Why?
|
| Malondialdehyde | 1 | 2010 | 16 | 0.080 |
Why?
|
| MicroRNAs | 1 | 2017 | 711 | 0.080 |
Why?
|
| Dicarboxylic Acids | 1 | 2009 | 2 | 0.080 |
Why?
|
| Lipid Peroxides | 1 | 2009 | 11 | 0.080 |
Why?
|
| alpha-Tocopherol | 1 | 2009 | 18 | 0.080 |
Why?
|
| India | 1 | 2010 | 161 | 0.080 |
Why?
|
| Predictive Value of Tests | 1 | 2012 | 1114 | 0.070 |
Why?
|
| Oxygen Consumption | 1 | 2010 | 213 | 0.070 |
Why?
|
| Linear Models | 1 | 2010 | 409 | 0.070 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2012 | 742 | 0.070 |
Why?
|
| Hemodynamics | 1 | 2010 | 257 | 0.070 |
Why?
|
| Apolipoprotein A-I | 1 | 2008 | 23 | 0.070 |
Why?
|
| Hydrogen Peroxide | 1 | 2008 | 86 | 0.070 |
Why?
|
| Exercise Test | 1 | 2010 | 257 | 0.070 |
Why?
|
| Gene Expression Regulation, Enzymologic | 1 | 2008 | 134 | 0.070 |
Why?
|
| Cross-Sectional Studies | 2 | 2026 | 2699 | 0.070 |
Why?
|
| Peroxidase | 1 | 2008 | 70 | 0.070 |
Why?
|
| Calcium | 1 | 2010 | 589 | 0.060 |
Why?
|
| Oxygen | 1 | 2008 | 325 | 0.060 |
Why?
|
| Feces | 1 | 2026 | 117 | 0.060 |
Why?
|
| Arteriosclerosis | 1 | 2005 | 32 | 0.060 |
Why?
|
| Clinical Trials as Topic | 1 | 2008 | 466 | 0.050 |
Why?
|
| Physical Conditioning, Animal | 1 | 2005 | 45 | 0.050 |
Why?
|
| Obesity | 1 | 2012 | 1269 | 0.050 |
Why?
|
| Disease Progression | 1 | 2008 | 1218 | 0.050 |
Why?
|
| Mice, Inbred C57BL | 2 | 2008 | 3468 | 0.050 |
Why?
|
| Metformin | 1 | 2024 | 76 | 0.050 |
Why?
|
| Platelet Function Tests | 1 | 2022 | 11 | 0.050 |
Why?
|
| Adenosine Diphosphate | 1 | 2022 | 43 | 0.050 |
Why?
|
| Disease Models, Animal | 1 | 2008 | 2294 | 0.040 |
Why?
|
| Antidepressive Agents | 1 | 2022 | 230 | 0.040 |
Why?
|
| Platelet Aggregation Inhibitors | 1 | 2022 | 235 | 0.040 |
Why?
|
| Young Adult | 1 | 2010 | 4831 | 0.040 |
Why?
|
| Adolescent | 1 | 2010 | 6377 | 0.040 |
Why?
|
| Aged, 80 and over | 1 | 2008 | 5608 | 0.030 |
Why?
|
| Receptors, LDL | 2 | 2009 | 35 | 0.030 |
Why?
|
| Cohort Studies | 1 | 2024 | 2632 | 0.030 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2025 | 2248 | 0.030 |
Why?
|
| Alzheimer Disease | 1 | 2022 | 770 | 0.030 |
Why?
|
| Oxidants | 1 | 2010 | 19 | 0.020 |
Why?
|
| Linoleic Acids | 1 | 2009 | 9 | 0.020 |
Why?
|
| Pyruvic Acid | 1 | 2009 | 14 | 0.020 |
Why?
|
| Chromatography, Thin Layer | 1 | 2009 | 18 | 0.020 |
Why?
|
| Spectrophotometry, Infrared | 1 | 2009 | 26 | 0.020 |
Why?
|
| Chromatography, Liquid | 1 | 2009 | 130 | 0.020 |
Why?
|
| Salicylates | 1 | 2008 | 9 | 0.020 |
Why?
|
| Receptors, Aryl Hydrocarbon | 1 | 2008 | 16 | 0.020 |
Why?
|
| Mass Spectrometry | 1 | 2009 | 312 | 0.020 |
Why?
|
| Hepatocytes | 1 | 2008 | 225 | 0.020 |
Why?
|
| Gene Silencing | 1 | 2008 | 421 | 0.010 |
Why?
|
| CD36 Antigens | 1 | 2005 | 27 | 0.010 |
Why?
|
| PPAR gamma | 1 | 2005 | 77 | 0.010 |
Why?
|
| Rats | 1 | 2008 | 2018 | 0.010 |
Why?
|
| Mice, Knockout | 1 | 2009 | 2149 | 0.010 |
Why?
|
| Biological Transport | 1 | 2005 | 295 | 0.010 |
Why?
|
| Proteins | 1 | 2010 | 764 | 0.010 |
Why?
|
| Models, Biological | 1 | 2009 | 1217 | 0.010 |
Why?
|
| Cell Line, Tumor | 1 | 2008 | 1613 | 0.010 |
Why?
|
| RNA, Small Interfering | 1 | 2008 | 969 | 0.010 |
Why?
|